Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line

Journal of Biological Chemistry

Volumn 289, Issue 34, 2014, Pages 23786-23795

  Maeda, Sakae ^a   Wada, Hiroshi ^a   Naito, Yoko ^a   Nagano, Hiroaki ^a   Simmons, Szandor ^a,b   Kagawa, Yoshinori ^a   Naito, Atsushi ^a   Kikuta, Junichi ^a,b   Ishii, Taeko ^a   Tomimaru, Yoshito ^a   Hama, Naoki ^a   Kawamoto, Koichi ^a   Kobayashi, Shogo ^a   Eguchi, Hidetoshi ^a   Umeshita, Koji ^a   Ishii, Hideshi ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   Ishii, Masaru ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; CELL CULTURE; GLYCOPROTEINS;

ANTICANCER DRUG; BIOCHEMICAL ASSAY; CELL-CYCLE ARREST; CLINICAL PRACTICES; HEPATOCELLULAR CARCINOMA; HEPATOCELLULAR CARCINOMA CELL; SIGNALING PATHWAYS; TIME-LAPSE IMAGING;

CELL DEATH;

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; CASPASE 3; CASPASE 7; FLUORESCENCE UBIQUINATION BASED CELL CYCLE INDICATOR; FLUORESCENT DYE; FLUOROURACIL; INTERFERON ALPHA TYPE 2 RECEPTOR; JANUS KINASE; PROTEIN P21; PROTEIN P53; PROTEIN P63; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR2 PROTEIN, HUMAN; PRIMER DNA;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; CELL TRACKING; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIME LAPSE IMAGING; UPREGULATION; CELL CYCLE; DRUG EFFECTS; FLOW CYTOMETRY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84906569017     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.551879     Document Type: Article

References (32)

1. Venook, A. P., Papandreou, C., Furuse, J., and de Guevara, L. L. (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15, Suppl. 4, 5-13
2. Rehermann, B., and Nascimbeni, M. (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229
3. Gutterman, J. U. (1994) Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. U.S.A. 91, 1198-1205
4. Pestka, S. (2007) The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047-20051
5. Platanias, L. C. (2005) Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5, 375-386
6. Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., and Taniguchi, T. (2003) Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523
7. Nagano, H., Miyamoto, A., Wada, H., Ota, H., Marubashi, S., Takeda, Y., Dono, K., Umeshita, K., Sakon, M., and Monden, M. (2007) Interferon-α and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110, 2493-2501
8. Ota, H., Nagano, H., Sakon, M., Eguchi, H., Kondo, M., Yamamoto, T., Nakamura, M., Damdinsuren, B., Wada, H., Marubashi, S., Miyamoto, A., Dono, K., Umeshita, K., Nakamori, S., Wakasa, K., and Monden, M. (2005) Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-Arterial 5-fluorouracil: role of type 1 interferon receptor expression. Br. J. Cancer 93, 557-564
9. Sangfelt, O., Erickson, S., and Grander, D. (2000) Mechanisms of interferon- induced cell cycle arrest. Front. Biosci. 5, D479-D487
10. Kondo, M., Nagano, H., Wada, H., Damdinsuren, B., Yamamoto, H., Hiraoka, N., Eguchi, H., Miyamoto, A., Yamamoto, T., Ota, H., Nakamura, M., Marubashi, S., Dono, K., Umeshita, K., Nakamori, S., Sakon, M., and Monden, M. (2005) Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular carcinoma cells. Clin. Cancer Res. 11, 1277-1286
11. Yano, H., Yanai, Y., Momosaki, S., Ogasawara, S., Akiba, J., Kojiro, S., Moriya, F., Fukahori, S., Kurimoto, M., and Kojiro, M. (2006) Growth inhibitory effects of interferon-α subtypes vary according to human liver cancer cell lines. J. Gastroenterol. Hepatol. 21, 1720-1725
12. Sangfelt, O., Erickson, S., Castro, J., Heiden, T., Einhorn, S., and Grandér, D. (1997) Induction of apoptosis and inhibition of cell growth are independent responses to interferon-α in hematopoietic cell lines. Cell Growth Differ. 8, 343-352
13. Murphy, D., Detjen, K. M., Welzel, M., Wiedenmann, B., and Rosewicz, S. (2001) Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33, 346-356
14. Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., Imamura, T., Ogawa, M., Masai, H., and Miyawaki, A. (2008) Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487-498
15. Morita, S., Kojima, T., and Kitamura, T. (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066
16. Nishikawa, K., Nakashima, T., Hayashi, M., Fukunaga, T., Kato, S., Kodama, T., Takahashi, S., Calame, K., and Takayanagi, H. (2010) Blimp1- mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl. Acad. Sci. U.S.A. 107, 3117-3122
17. Copeland, N. G., Gilbert, D. J., Schindler, C., Zhong, Z., Wen, Z., Darnell, J. E., Jr., Mui, A. L., Miyajima, A., Quelle, F. W., and Ihle, J. N. (1995) Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29, 225-228
18. Quelle, F. W., Thierfelder, W., Witthuhn, B. A., Tang, B., Cohen, S., and Ihle, J. N. (1995) Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor. J. Biol. Chem. 270, 20775-20780
19. Damdinsuren, B., Nagano, H., Wada, H., Noda, T., Natsag, J., Marubashi, S., Miyamoto, A., Takeda, Y., Umeshita, K., Doki, Y., Dono, K., and Monden, M. (2007) Interferon α receptors are important for antiproliferative effect of interferon-α against human hepatocellular carcinoma cells. Hepatol. Res. 37, 77-83
20. Barchet, W., Cella, M., Odermatt, B., Asselin-Paturel, C., Colonna, M., and Kalinke, U. (2002) Virus-induced interferon α production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 195, 507-516
21. Taylor, R. C., Cullen, S. P., and Martin, S. J. (2008) Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231-241
22. Shah, M. A., and Schwartz, G. K. (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7, 2168-2181
23. Huberman, J. A. (1981) New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase α. Cell 23, 647-648
24. Cagatay, T., and Ozturk, M. (2002) P53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene 21, 7971-7980
25. Yoshikawa, H., Nagashima, M., Khan, M. A., McMenamin, M. G., Hagiwara, K., and Harris, C. C. (1999) Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18, 3415-3421
26. Hagiwara, K., McMenamin, M. G., Miura, K., and Harris, C. C. (1999) Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 59, 4165-4169
27. Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze-Bergkamen, H., Lena, A. M., Candi, E., Terrinoni, A., Catani, M. V., Oren, M., Melino, G., Krammer, P. H., Stremmel, W., and Muller, M. (2005) TAp63α induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 24, 2458-2471
28. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684
29. Dohn, M., Zhang, S., and Chen, X. (2001) p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20, 3193-3205
30. Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Eguchi, H., Tanemura, M., Tomimaru, Y., Osuga, K., Umeshita, K., Doki, Y., and Mori, M. (2011) Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 80, 63-69
31. Waltermann, A., Kartasheva, N. N., and Dobbelstein, M. (2003) Differential regulation of p63 and p73 expression. Oncogene 22, 5686-5693
32. Fogal, V., Hsieh, J. K., Royer, C., Zhong, S., and Lu, X. (2005) Cell cycledependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. EMBO J. 24, 2768-2782